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Objectives High levels of soluble receptor for advanced
glycation end products (sRAGE) have been shown to have
an atheroprotective role; however, no data are available on
this molecule in acute coronary syndromes (ACS). We
evaluated sRAGE levels in patients with non-ST segment
elevation ACS (NSTE-ACS) or with chronic stable angina.
Methods We studied 265 patients, 190 of whom had
NSTE-ACS and 75 had chronic stable angina.
Results Plasma sRAGE values were comparable in the
two groups (P=0.19). However, in the patients with NSTE-
ACS, sRAGE levels were significantly higher in patients
with cardiac troponin-I (cTnI) of more than or equal to
0.04lg/l compared with those with cTnI of less than
0.04lg/l [758 pg/ml (493–1536pg/ml) vs. 454pg/ml
(167–899pg/ml); P=0.0037]. A significant correlation
(r=0.323, P=0.0045) was found between sRAGE and cTnI
levels in patients with NSTE-ACS.
Conclusion Plasma sRAGE levels are elevated in patients
with NSTE-ACS with positive cTnI, suggesting that they
could be related to myocardial cell damage. Coron Artery
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Introduction
Biomarkers play an important role in the diagnosis of acute
coronary syndromes (ACS), especially in unstable angina
and non-ST-segment elevation (NSTE) myocardial infarc-
tion. Among these, cardiac troponin and creatine kinase
appear to be the most sensitive and specific markers of
myocardial injury [1,2]. However, ideal biomarkers offering
early detection, risk stratification, monitoring disease
progression, and treatment efficacy remain to be eluci-
dated. As NSTE-ACS are clinically heterogeneous, the
assessment of several markers would provide complemen-
tary information to that of more established and conven-
tional ones, and enable clinicians to stratify risk more
effectively in patients with ACS.
In recent years, the circulating form of receptor for
advanced glycation end products (RAGE), called soluble
RAGE (sRAGE), able to competitively inhibit ligand
binding to cell-surface RAGE, has been reported as an
emerging biomarker in cardiovascular, metabolic and
inflammatory diseases [3,4].
The interaction of RAGE with its ligands – high-mobility
group box 1(HMGB1), advanced glycation end products
(mainly N-E-(carboxymethyl)lysine adducts) and S100,
among others – leads to cell activation resulting in
production of cytokines, growth factors, and adhesion
molecules [5,6]. The key finding that RAGE is a
multiligand receptor unifies the concept that in diabetes
and aging, innate and adaptive inflammatory mechanisms
contribute to pathogenesis of tissue injury [7].
The sRAGE, composed of only the extracellular ligand-
binding domain, is generated by alternative splicing or
proteolytic cleavage of full-length RAGE [8]. It circulates
in human plasma and is still able to bind ligands and thus
antagonize RAGE signalling [3,4]. This assumption has
been supported by animal experiments, in which admin-
istration of sRAGE to atherosclerotic mice slowed the
progression of atherosclerosis, and by clinical studies in
which low levels of sRAGE were associated with coronary
artery disease, carotid and femoral atherosclerosis, as well
as with metabolic syndrome [9–11], suggesting a
vasculoprotective role for this molecule.
Importantly, RAGE ligands are closely involved in the
events of ischemia/reperfusion injury through RAGE axis,
whereas the administration of sRAGE mitigates the
adverse impact of ischemia/reperfusion injury in the
heart, revealing a cardioprotective effect [12–14].
It is likely that in an acute inflammatory setting, plasma
levels of sRAGE may increase. It has recently been shown
that sRAGE levels are elevated in patients with septic
shock [3], and in healthy volunteers treated with
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endotoxin they increased after 5 h [15]. Levels of sRAGE
are upregulated during intratracheal lipopolysaccharide-
induced lung injury [16].
We have recently reported that in patients with carotid
atherosclerosis, sRAGE levels were higher in sympto-
matic than asymptomatic patients [17].
The aim of this study was to investigate the role of




Two hundred and sixty-five patients, consecutively
admitted to our Coronary Care Unit with coronary artery
disease and undergoing diagnostic coronary angiography,
were enrolled. A total of 190 patients had NSTE-ACS and
75 had CSA. Exclusion criteria included: ST-segment
elevation myocardial infarction (STEMI), previous his-
tory of coronary artery bypass grafting, significant heart
valve disease, cardiogenic shock, congestive heart failure,
renal or liver diseases, infectious, chronic inflammatory or
immunologic diseases, malignancies, and serum creati-
nine level of more than 106.08 mmol/l. None of the
participating patients were taking vitamins or antioxidant
dietary supplements, nonsteroidal anti-inflammatory
drugs, hormone replacement therapy, or anticoagulants.
The local ethics committee approved the study protocol,
and all patients signed written informed consent.
Angiography was performed in all patients according to
standard indications [18,19].
Blood samples and laboratory analyses
In patients with CSA, blood samples were collected at
the time of angiography but before the injection of
contrast material. In patients with NSTE-ACS, blood was
drawn on admission, within 24 h after the last ischemic
episode and before angiography (mean time was
12.6±5.8 h within 4–24 h).
Blood samples were drawn in tubes without additives,
containing heparin or citrate (for routine biochemistry).
Creatinine, total cholesterol, high-density lipoprotein
cholesterol, triglycerides, glucose and high-sensitivity
C-reactive protein (CRP) were determined using routine
laboratory procedures. Plasma and serum samples were
centrifuged at 41C, immediately divided in aliquots and
stored at – 801C until analysis. All laboratory work was
done in blinded manner with respect to the identity of
the samples.
Soluble receptor for advanced glycation end products
assay
For sRAGE determination, blood samples were collected
in tubes containing Na2EDTA, and plasma sRAGE levels
were determined using a double-sandwich enzyme-linked
immunosorbent assay (ELISA) kit (DuoSet ELISA
development kit; R and D Systems, Minneapolis,
Minnesota, USA) as described previously [11]. Intra-
assay and interassay values of variation coefficient were
5.9 and 8.2%, respectively. The lower limit of detection of
sRAGE was 21.5 pg/ml.
Cardiac troponin I assay
To evaluate cardiac troponin I (cTnI) concentrations,
blood samples were collected in tubes with lithium
heparin. Plasma samples were analyzed using the Access
AccuTnI assay (Beckman Coulter, Villepinte, France).
The assay has a detection limit of 0.014 mg/l and a
coefficient of variation of 10% at a value of 0.06 mg/l. The
99th percentile of a reference control population is
0.04 mg/l. As the 99th percentile of a reference population
has been defined to represent evidence of myocardial
necrosis [1,20]. The patients were classified as cTnI
positive if the cTnI value was more than or equal to
0.04 mg/l.
Power calculation
Sample size was calculated with the Stata software
(version 9.2; Stata Corp. College Station, Texas, USA)
by the estimated power for two-sample comparison of
means of log-transformed RAGE values. A sample size of
144 patients (72 per arm) would provide 95% power to
detect differences of 25–30% in the sRAGE levels
between the two groups in a two-sided test at an a level
of 0.05. We therefore recruited in excess of this figure to
be fully confident in our data.
The subgroup analyses (above vs. below the cutoff of
cTnI) had not been prespecified and as the sample size
was determined by screening the cutoff of cTnI, the test
power associated with the sample size was calculated
a posteriori for the main variable of the study (sRAGE) and
the power value found was 99.9% (with a two-sided type
1 error of 1%).
Statistical analysis
Data with a normal distribution are given as mean±
standard deviation. Variables with a skewed distribution
are expressed as median and interquartile range. Group
differences were analyzed by the Student t-test, and the
w2-test for normally distributed, and noncontinuous
variables, respectively. Variables with a non-normal
distribution were logarithmically transformed before each
analysis. The correlations were assessed by the Pearson
correlation analysis. A two-sided P value of less than 0.05
was considered significant. Data were analyzed with the
use of statistical software SPSS 13.0 (SPSS Inc., Chicago,
Illinois, USA).
Results
The clinical and angiographic details of all patients are
summarized in Table 1. The NSTE-ACS and the CSA
groups did not differ significantly for sex, age, occurrence
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of smoking, obesity, diabetes, family history for coronary
artery disease, dyslipidemia, body mass index, coronary
angiographic findings, and cardiac medications. Among
biochemical parameters, high-density lipoprotein choles-
terol values were lower in the NSTE-ACS than in the
CSA group (P=0.02). As expected, CRP and cTnI levels
were significantly higher in the first group than in the
second (P=0.0001 and 0.0033, respectively; Table 2),
whereas sRAGE levels did not differ between two groups
[429 pg/ml (250–841 pg/ml) vs. 461 pg/ml (260–678 pg/
ml), P=0.19; Table 2].
Within the NSTE-ACS group, 58 patients (30.5%) had
cTnI of more than 0.04 mg/l (Table 3).
Elevated sRAGE values were found in patients with
NSTE-ACS with positive cTnI (cTnI >0.04 mg/l) than
in patients with NSTE-ACS with negative cTnI () [cTnI
<0.04 mg/l; 758 pg/ml (493–1536 pg/ml) vs. 454 pg/ml
(167–899 pg/ml); P=0.0037; Table 3].
In contrast, no difference was found in plasma CRP
concentrations into the NSTE-ACS group between those
patients with raised and those with normal cTnI [41mg/l
(21.7–203mg/l) vs. 40mg/l (14.8–100.5mg/l); P=0.29;
Table 3].
In addition, plasma levels of sRAGE correlated with the
levels of cTnI (r=0.323, P=0.0045) in patients with
NSTE-ACS but not with all other biochemical para-
meters or with the number and extent of diseased vessels
found on angiography (data not shown).
Discussion
ACS is a complex disease involving macrophage activity,
oxidative stress, tissue remodelling, necrosis, and throm-
bosis. As biomarkers may reflect various pathophysiologi-
cal processes, the use of multimarker strategy could allow
risk stratification and provide prognostic information in
patients with ACS. For instance, a multimarker study
combining baseline levels of cTnI, CRP, and brain
natriuretic peptide among patients with NSTE myocar-
dial infarction identified a 6-fold to 13-fold gradient of
mortality risk between those in whom all three markers
were elevated and those without elevation of any
marker [21]. In contrast to our first hypothesis of the
study, we did not find different values of sRAGE between
patients with CSA and NSTE-ACS. In agreement with
our results, it has been recently reported that sRAGE
levels did not differ between ACS and stable angina
groups, whereas they were higher in ACS than in control
groups [22]. The same study has demonstrated that
serum levels of S100 proteins (RAGE ligands) were
higher in ACS than in both stable angina and control
groups, and the expression of these proteins were related
to myocardial injury in patients with ACS and in rat
models of myocardial infarction, supporting the role of
RAGE and its ligands in myocardial infarction and
cardiovascular diseases [22].
The lack of significativity of serum levels of sRAGE
between NSTE-ACS and CSA groups could depend by
many factors, including the pharmacological treatments,
such as statins and antihypertensive drugs [23].
Nevertheless, this is the first study that shows elevated
circulating sRAGE levels in patients with NSTE-ACS
with an increased cTnI level compared with those with
Table 1 Baseline demographic and clinical characteristics of all
patients
NSTE-ACS CSA
n=190 n=75 P value
Age (years) 65±10 62±10 0.14
Male (%) 76 86 0.30
Body mass index, kg/m2 26.8±3.5 25.9 ±3.6 0.37
Obesity (%) 29 33 0.69
Family history (%) 46 56 0.16
Diabetes mellitus (%) 25 27 0.63
Smoking (%) 56 60 0.39
Hypertension (%) 67 65 0.84
Medications (%)
Antihypertension treatment 75 85 0.49
Lipid-lowering treatment 56 62 0.42
Hypoglycemic treatment 22 25 0.59
Antithrombotic treatment 80 82 0.83
Coronary angiography
Left ventricular ejection fraction 54.2±10.2 58.2 ±7.0 0.23
One-vessel disease (%) 44 55 0.48
Multivessel disease (%) 56 45 0.45
CSA, chronic stable angina; NSTE-ACS, non-ST segment elevation acute
coronary syndromes; SD, standard deviation.
Values are means ±SD or frequency (%).
Table 2 Biochemical characteristics of study patients
NSTE-ACS CSA
n=190 n=75 P value
Glucose (mmol/l) 6.55±2.6 6.2 ±2.05 0.34
Total cholesterol (mmol/l) 4.27±1.34 3.88±1.42 0.06
Triglycerides (mmol/l) 1.49±0.68 1.33±0.69 0.09
HDL-C (mmol/l) 0.98±0.28 1.08±0.23 0.02
LDL-C (mmol/l) 3.26±0.9 3.15±1.06 0.58
Creatinine (mmol/l) 88.85±28.11 82.2 ±23.9 0.20
CRP (mg/l) 25.9 (8–74) 5.1(1.6–17.9) 0.0001
cTnI (mg/l) 0.34 (0.113–0.648) 0.045 (0.01–0.26) 0.0033
sRAGE (pg/ml) 429 (250–841) 461 (260–678) 0.19
CRP, C-reactive protein; CSA, chronic stable angina; cTn1, cardiac troponin-I;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; NSTE-ACS, non-ST segment elevation acute coronary syndromes;
SD, standard deviation; sRAGE, soluble receptor for advanced glycation end
product.
Values are means ±SD or median (interquartile range).
Table 3 Plasma levels of soluble receptor for advanced glycation
end product in patients with non-ST segment elevation acute
coronary syndromes
cTnI negative ( < 0.04 mg/l) cTnI positive ( > 0.04 mg/l)
n=132 n=58 P value
sRAGE (pg/ml) 454 (167–899) 758 (493–1536) 0.0037
CRP (mg/l) 40 (14.8–100.5) 41 (21.7–203) 0.553
CRP, C-reactive protein; cTn1, cardiac troponin-I; NSTE-ACS, non-ST segment
elevation acute coronary syndromes; sRAGE, soluble receptor for advanced
glycation end product.
Values are median (interquartile range).
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normal cTnI. Although this is an observational study and
thus we cannot draw conclusions about causality, never-
theless these relationships lead us to believe that sRAGE
may arise after injury. Acute myocardial ischemia and
injury could be prominent stimuli that raise the release of
sRAGE. A likely pathway for sRAGE production in
patients with NSTE-ACS with positive cTnI is the
myocardial injury that induces inflammatory reactions.
The cell-surface RAGE is expressed by multiple inflam-
matory cells, including neutrophils, monocyte macro-
phages, and lymphocytes. Ligands of RAGE, particularly
the endogen danger signal HMGB1 released rapidly
during necrosis and actively by inflammatory cells, sustain
vascular injury. Accordantly, increased levels of serum
HMGB1 have been shown in patients with ACS [24].
Therefore, the increase in HMGB1 and inflammatory
cytokines leads to a cascade of inflammation and could
stimulate macrophages to secrete sRAGE. In addition,
another trigger for the sRAGE increase could be the
RAGE-ligand N-E-(carboxymethyl)lysine, which recently
has been found to be higher in plasma of patients with
ACS with positivity to cTnT [25].
Alternatively, an increased proteolytic activity during
ACS, by matrix metalloproteinase-9 or disintegrin-like
metalloproteinase, ADAM10 (two enzymes involved in
RAGE shedding [26]), could generate more sRAGE.
In a recent study in minipigs with ischemia/reperfusion
injury, it has been reported that intracoronary sRAGE
administration decreases myocardial TGF-b1 expression,
myocardial fibrotic lesion formation, and cardiac remodel-
ling, suggesting that inhibition of RAGE-mediated
inflammation is crucial for cardioprotection against
ischemia/reperfusion injury [27].
In agreement with several reports, we confirm that
plasma CRP levels were higher in patients with NSTE-
ACS than in those with CSA [28,29]. However, in our
study, unlike sRAGE, CRP level was not higher in
patients with NSTE-ACS with positive cTnI than in
those with negative cTnI and did not correlate with each
other, suggesting that CRP and sRAGE may be com-
plementary and reveal different features of the disease.
The measurement of sRAGE shows promise and needs to
be more thoroughly evaluated for commercial develop-
ment for implementation into routine clinical and
laboratory practice. After all, larger clinical studies are
indicated to review the role of sRAGE as a surrogate
biomarker of myocardial injury. More widespread use of
sRAGE assays for patients with NSTE-ACS will therefore
facilitate prognostication and improve tailoring of man-
agement. Crossing boundaries from research to clinical
application will require replication in multiple settings
and experimental evidence supporting a pathophysiologic
role and, ideally, interventional trials showing that
monitoring single or multiple biomarkers improves out-
comes.
Study limitation
The main limitation of this study is that we did not
recruit patients with more severe myocardial injury,that
is, patients with STEMI. Actually, these data were
unexpected because before the beginning of the study,
we hypothesized that we might see significant differ-
ences in sRAGE levels between CSA and NSTE-ACS
groups. Therefore, at the moment we do not know
whether plasma sRAGE levels in patients with STEMI
are even higher than those in patients with NSTE-ACS.
In addition, in a further step, longitudinal studies should
be performed to evaluate whether sRAGE measurement
might be useful in monitoring the progression or
remission of ACS.
A second caveat of this study is the lack of RAGE ligand
assessment that could provide a more complete picture of
the complex interaction between RAGE tissue, ligands
and sRAGE.
Third, the ELISA system for sRAGE determination
cannot distinguish among diverse sRAGE splice variants.
However, this limitation is only apparent; whether
sRAGE or esRAGE is produced, in both cases the
ligand-binding domain is intact, enabling soluble receptor
isoforms to sequester RAGE ligands and promote their
disposal.
Conclusion
Although our cross-sectional analysis and correlations do
not imply causality, the inter-relationships between
sRAGE levels and cTnI in patients with NSTE-ACS is
biologically plausible. We speculate that sRAGE is
responsive to stimuli in the local environment. In the
myocardial injury context, increased proteolysis at the cell
surface or major secretion by activated inflammatory cells
results in higher levels of circulating sRAGE. Conceivably,
high levels of sRAGE are part of a counter-regulatory
mechanism elicited by vascular/myocardial injury and
aimed at RAGE signalling suppression.
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